collection
MENU ▼
Read by QxMD icon Read
search

MMCBreast Collection

shared collection
348 papers 100 to 500 followers
https://www.readbyqxmd.com/read/29445299/choosing-wisely-after-publication-of-level-i-evidence-in-breast-cancer-radiotherapy
#1
Joshua R Niska, Sameer R Keole, Barbara A Pockaj, Michele Y Halyard, Samir H Patel, Donald W Northfelt, Richard J Gray, Nabil Wasif, Carlos E Vargas, William W Wong
Background: Recent trials in early-stage breast cancer support hypofractionated whole-breast radiotherapy (WBRT) as part of breast-conserving therapy (BCT). Evidence also suggests that radiotherapy (RT) omission may be reasonable for some patients over 70 years. Among radiation-delivery techniques, intensity-modulated RT (IMRT) is more expensive than 3-dimensional conformal RT (3DCRT). Based on this evidence, in 2013, the American Society for Radiation Oncology (ASTRO) recommended hypofractionated schedules for women aged ≥50 years with early-stage breast cancer and avoiding routine use of IMRT for WBRT...
2018: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29450753/use-of-breast-imaging-after-treatment-for-locoregional-breast-cancer-aft-01
#2
Taiwo Adesoye, Jessica R Schumacher, Heather B Neuman, Stephen Edge, Daniel McKellar, David P Winchester, Amanda B Francescatti, Caprice C Greenberg
BACKGROUND: Annual mammography is recommended after breast cancer treatment. However, studies suggest its under-utilization for Medicare patients. Utilization in the broader population is unknown, as is the role of breast magnetic resonance imaging (MRI). Understanding factors associated with imaging use is critical to improvement of adherence to recommendations. METHODS: A random sample of 9835 eligible patients receiving surgery for stages 2 and 3 breast cancer from 2006 to 2007 was selected from the National Cancer Database for primary data collection...
February 15, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29427213/treatment-strategies-in-octogenarians-with-early-stage-high-risk-breast-cancer
#3
Anita Mamtani, Julie J Gonzalez, Dayna T Neo, Robb S Friedman, Abram Recht, Michele R Hacker, Ranjna Sharma
BACKGROUND: Octogenarians with early-stage breast cancer often have low-risk tumor biology. However, optimal treatment strategies for those with high-risk biology remain unclear. METHODS: We reviewed the records of women ages 80-89 years with biopsy-proven, Stage I-II invasive breast cancer who were referred for surgical evaluation from January 2001 through December 2010. High-risk was defined as human epidermal growth factor receptor-positive (HER2+), triple-negative (TN), or histologic grade 3 disease...
February 9, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29329006/ongoing-unmet-needs-in-treating-estrogen-receptor-positive-her2-negative-metastatic-breast-cancer
#4
REVIEW
Gül A Başaran, Chris Twelves, Véronique Diéras, Javier Cortés, Ahmad Awada
Estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (MBC) is the most common MBC subtype and currently remains incurable, with a median overall survival of 24.8 months (95% confidence interval, 21.3-30.3). Common sites of metastases are bone, viscera, and brain, causing significant symptoms that negatively affect patient functioning, quality of life (QoL), and work productivity. Guidelines state that endocrine therapy (ET) is preferable to chemotherapy as first-line treatment for patients with ER+ MBC, regardless of limited visceral metastases, unless rapid tumor response is required or ET resistance is suspected...
February 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29397949/a-lymphedema-surveillance-program-for-breast-cancer-patients-reveals-the-promise-of-surgical-prevention
#5
Mandee Hahamoff, Nachi Gupta, Derly Munoz, Bernard T Lee, Pamela Clevenger, Christiana Shaw, Lisa Spiguel, Dhruv Singhal
BACKGROUND: Breast cancer-related lymphedema (BCRL) is one of the most significant survivorship issues in breast cancer management. Presently, there is no cure for BCRL. The single greatest risk factor for developing BCRL is an axillary lymph node dissection (ALND). Lymphatic Microsurgical Preventative Healing Approach (LYMPHA) is a surgical procedure to reduce the risk of lymphedema in patients undergoing an ALND. We present our single institution results after offering LYMPHA in the context of an established lymphedema surveillance program...
February 1, 2018: Journal of Surgical Research
https://www.readbyqxmd.com/read/29387884/incidence-and-outcome-of-breast-biopsy-procedures-during-follow-up-after-treatment-for-breast-cancer
#6
Raquel F D van la Parra, Kaiping Liao, Benjamin D Smith, Wei T Yang, Jessica W T Leung, Sharon H Giordano, Henry M Kuerer
Importance: No comprehensive data are available regarding the frequency of breast biopsies performed during follow-up of treatment for invasive breast cancer. Objective: To determine how often patients treated for breast cancer require breast biopsies during follow-up. Design, Setting, and Participants: This nationwide population-based cohort study included 41 510 patients 64 years or younger in a commercial insurance database and 80 369 patients 66 years or older in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database...
January 31, 2018: JAMA Surgery
https://www.readbyqxmd.com/read/29388016/a-retrospective-prognostic-evaluation-analysis-using-the-8th-edition-of-the-american-joint-committee-on-cancer-staging-system-for-breast-cancer
#7
Sae Byul Lee, Guiyun Sohn, Jisun Kim, Il Yong Chung, Jong Won Lee, Hee Jeong Kim, Beom Seok Ko, Byung Ho Son, Sei-Hyun Ahn
PURPOSE: Breast cancer is a group of diseases with different intrinsic molecular subtypes. However, anatomic staging alone is insufficient to determine prognosis. The present study analyzed the prognostic value of the American Joint Committee for Cancer (AJCC) 8th edition cancer staging system. METHODS: This retrospective, single-center study included breast cancer cases diagnosed from January 1999 to December 2008. We restaged patients based on the 8th edition AJCC cancer staging system and analyzed the prognostic value of the anatomic and prognostic staged groups...
January 31, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29374852/lymphovascular-invasion-after-neoadjuvant-chemotherapy-is-strongly-associated-with-poor-prognosis-in-breast-carcinoma
#8
Anne-Sophie Hamy, Giang-Thanh Lam, Enora Laas, Lauren Darrigues, Thomas Balezeau, Julien Guerin, Alain Livartowski, Benjamin Sadacca, Jean-Yves Pierga, Anne Vincent-Salomon, Florence Coussy, Veronique Becette, Hélène Bonsang-Kitzis, Roman Rouzier, Jean-Guillaume Feron, Gabriel Benchimol, Marick Laé, Fabien Reyal
PURPOSE: Few studies evaluated the prognostic value of the presence of lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC). METHODS: The association between LVI and survival was evaluated in a cohort of BC patients treated by NAC between 2002 and 2011. Five post-NAC prognostic scores (ypAJCC, RCB, CPS, CPS + EG and Neo-Bioscore) were evaluated and compared with or without the addition of LVI. RESULTS: Out of 1033 tumors, LVI was present on surgical specimens in 29...
January 27, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29365031/unravelling-triple-negative-breast-cancer-molecular-heterogeneity-using-an-integrative-multiomic-analysis
#9
Y Bareche, D Venet, M Ignatiadis, P Aftimos, M Piccart, F Rothe, C Sotiriou
Background: Recent efforts of genome-wide gene expression profiling analyses have improved our understanding of the biological complexity and diversity of triple negative breast cancers (TNBCs) reporting, at least 6 different molecular subtypes of TNBC namely Basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL) and luminal androgen receptor (LAR). However, little is known regarding the potential driving molecular events within each subtype, their difference in survival and response to therapy...
January 22, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29366482/breast-cancer-in-women-under-50-most-are-not-high-risk
#10
Thomas Sutton, Phil Reilly, Nathalie Johnson, Jennifer R Garreau
BACKGROUND: In 2009, the United States Preventive Services Task Force changed the recommended starting age for annual screening mammography from 40 to 50 for non-"high risk" women. In 2015, the American Cancer Society issued similar guidelines, with a starting age of 45. Our hypothesis is that most women diagnosed with breast cancer in this age group do not fall into a "high risk" category. METHODS: A retrospective review of women less than 50 years of age diagnosed with breast cancer in the Legacy Health Care System was performed for January 2013 through December 2015...
January 11, 2018: American Journal of Surgery
https://www.readbyqxmd.com/read/29352368/endocrine-therapy-and-related-issues-in-hormone-receptor-positive-early-breast-cancer-a-roundtable-discussion-by-the-breast-cancer-therapy-expert-group-bcteg
#11
REVIEW
Jame Abraham, Humberto Caldera, Robert Coleman, Anthony Elias, Matthew P Goetz, Muaiad Kittaneh, Elyse Lower, Reshma Mahtani, E Terry Mamounas, Mark Pegram, Hope Rugo, Lee Schwartzberg, Tiffany Traina, Chuck Vogel
PURPOSE: Management of breast cancer is a rapidly evolving field, and, although evidence-based guidelines are available for clinicians to provide direction on critical issues in patient care, clinicians often left to address these issues in the context of community practice situations with their patients. These include the patient's comorbid conditions, actual versus perceived benefit of treatments, patient's compliance as well as financial/reimbursement issues, and long-term tolerability of therapy...
January 19, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29332137/variation-in-guideline-concordant-care-for-elderly-patients-with-metastatic-breast-cancer-in-the-united-states
#12
Philip D Poorvu, Ines Vaz-Luis, Rachel A Freedman, Nancy U Lin, William T Barry, Eric P Winer, Michael J Hassett
PURPOSE: Prior studies have identified shortcomings in the quality of care for early-stage breast cancer. Guidelines recommend systemic therapy for metastatic breast cancer (MBC), but few studies have examined guideline concordance for these patients. METHODS: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify patients aged ≥ 66 diagnosed in 2010-2011 with de novo MBC who were continuously enrolled in fee-for-service Medicare...
January 13, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29327298/the-impact-of-obesity-on-outcomes-for-patients-undergoing-mastectomy-using-the-acs-nsqip-data-set
#13
Mary Garland, Fang-Chi Hsu, Clancy Clark, Akiko Chiba, Marissa Howard-McNatt
PURPOSE: According to the World Health Organization (WHO), 34.7% of females in the United States are obese (BMI ≥ 30) in 2014, compared to 32.5% in 2010. The previous research has demonstrated high BMI as an independent risk factor for surgical complications after breast surgery. As more patients become obese, we sought to examine whether increasing obesity had an effect on outcomes of women who underwent a unilateral mastectomy without breast reconstruction. METHODS: The study reviewed the 2007-2012 ACS-NSQIP database and identified all patients who underwent a unilateral mastectomy without reconstruction...
January 11, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29326104/rethinking-neoadjuvant-chemotherapy-for-breast-cancer
#14
Jayant S Vaidya, Samuele Massarut, Hrisheekesh J Vaidya, Emma C Alexander, Thomas Richards, Jochem A Caris, Bhawna Sirohi, Jeffrey S Tobias
No abstract text is available yet for this article.
January 11, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29318276/association-of-screening-and-treatment-with-breast-cancer-mortality-by-molecular-subtype-in-us-women-2000-2012
#15
Sylvia K Plevritis, Diego Munoz, Allison W Kurian, Natasha K Stout, Oguzhan Alagoz, Aimee M Near, Sandra J Lee, Jeroen J van den Broek, Xuelin Huang, Clyde B Schechter, Brian L Sprague, Juhee Song, Harry J de Koning, Amy Trentham-Dietz, Nicolien T van Ravesteyn, Ronald Gangnon, Young Chandler, Yisheng Li, Cong Xu, Mehmet Ali Ergun, Hui Huang, Donald A Berry, Jeanne S Mandelblatt
Importance: Given recent advances in screening mammography and adjuvant therapy (treatment), quantifying their separate and combined effects on US breast cancer mortality reductions by molecular subtype could guide future decisions to reduce disease burden. Objective: To evaluate the contributions associated with screening and treatment to breast cancer mortality reductions by molecular subtype based on estrogen-receptor (ER) and human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu)...
January 9, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29316513/the-biology-of-male-breast-cancer
#16
REVIEW
Ian S Fentiman
Important differences have begun to emerge concerning the molecular profile of female and male breast cancer which may prove to be of therapeutic value. This review examined all the available data on the genomics of MBC. Most male cancers are ER+ve but without a corresponding increase in PR positivity and only a weaker association with estrogen-controlled markers such as PS2, HSP27 and Cathepsin-D. HER2 +ve cancers are rare in males and the role of androgen receptor is controversial. Although the Luminal A phenotype was the most frequent in both MBC and FBC, no Luminal B or HER2 phenotypes were found in males and the basal phenotype was very rare...
January 6, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29310037/a-nationwide-registry-based-cohort-study-of-the-mammaprint-genomic-risk-classifier-in-invasive-breast-cancer
#17
Floris H Groenendijk, Agnes Jager, Fatima Cardoso, Carolien H M van Deurzen
AIM: To evaluate the use of the MammaPrint assay, a 70-gene risk signature for early breast cancers, and to correlate genomic risk stratification with individual clinicopathological parameters and clinical risk as assessed by Adjuvant! Online. METHODS: A Dutch Pathology Registry (PALGA)-based cohort study consisting of 1916 patients for which 1946 MammaPrint assay results were synoptically reported from 2013 to 2016. We could retrospectively assess clinical risk for 1146 tumors (58...
January 5, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29132568/molecular-subtypes-and-local-regional-control-of-breast-cancer
#18
REVIEW
Simona Maria Fragomeni, Andrew Sciallis, Jacqueline S Jeruss
In the era of personalized medicine, there has been significant progress regarding the molecular analysis of breast cancer subtypes. Research efforts have focused on how classification of subtypes could provide information on prognosis and influence treatment planning. Although much is known about the impact of different molecular subtypes on disease-specific survival, more recent studies have investigated the role of the different molecular subtypes on local-regional recurrence. This is an area of active study, and in recent years there has been significant progress...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29300815/inhibited-trapped-or-adducted-the-optimal-selective-synthetic-lethal-mix-for-brcaness
#19
Andrew Tutt
No abstract text is available yet for this article.
December 28, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29298118/circulating-tumor-dna-guides-prognosis-in-metastatic-triple-negative-breast-cancer
#20
Andjelija Zivanovic Bujak, Sarah-Jane Dawson
No abstract text is available yet for this article.
January 3, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
label_collection
label_collection
6331
1
2
2018-01-05 21:51:06
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"